CN1166367C - Medicine for external application for curing psoriasis - Google Patents
Medicine for external application for curing psoriasis Download PDFInfo
- Publication number
- CN1166367C CN1166367C CNB011282800A CN01128280A CN1166367C CN 1166367 C CN1166367 C CN 1166367C CN B011282800 A CNB011282800 A CN B011282800A CN 01128280 A CN01128280 A CN 01128280A CN 1166367 C CN1166367 C CN 1166367C
- Authority
- CN
- China
- Prior art keywords
- medicine
- psoriasis
- external application
- paste
- calomelas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 201000004681 Psoriasis Diseases 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title description 4
- 241001161070 Calomela Species 0.000 claims abstract description 6
- QYZBCWXZSYTIOY-UHFFFAOYSA-N Mercuric oxide Chemical compound [O-2].[Hg+2] QYZBCWXZSYTIOY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940099259 vaseline Drugs 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 8
- 229910052957 realgar Inorganic materials 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 10
- 201000004624 Dermatitis Diseases 0.000 abstract description 2
- 206010048768 Dermatosis Diseases 0.000 abstract description 2
- 208000010668 atopic eczema Diseases 0.000 abstract description 2
- 208000017520 skin disease Diseases 0.000 abstract description 2
- 201000010153 skin papilloma Diseases 0.000 abstract description 2
- 230000000073 effect on psoriasis Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 231100000004 severe toxicity Toxicity 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- CUGMJFZCCDSABL-UHFFFAOYSA-N arsenic(3+);trisulfide Chemical compound [S-2].[S-2].[S-2].[As+3].[As+3] CUGMJFZCCDSABL-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940075397 calomel Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- 229940100892 mercury compound Drugs 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to externally applied medicine for treating psoriasis, which comprises the components by weight: 3 to 10 g of white downborne elixir, 5 to 15 g of calomelas and 3 to 10 portions of hydrargyri oxydum rubrum, and the components are prepared into fine powder to be regulated into externally applied paste with vaseline oil. The paste has the advantages of simple preparation method and low cost and has special effect on psoriasis. By three-year trial, the total effective rate can reach over 95%, and the medicine has certain curative effect on dermatosis such as eczema, flat warts, etc.
Description
Technical field: the present invention relates to a kind of medicine, the psoriasic medicine for external use of promptly a kind of treatment.
Background technology: psoriasis, modern medicine claim " psoriasis ", and when just sending out, the erythema pimple appears in patient skin, and rapid then expanded scope forms coin or map shape, covers squama, the visible thin film of scaling, and visible blood point under the thin film claims psoriasis vulgaris.If skin has pustule, and regular outbreak, psoriasis pustulosa be called.Soak into if skin is diffuse erythema, then be called erythrodermic psoriasis with a large amount of desquamations.At present, a lot of about the antipsoriatic method of rash, but how undesirable curative effect is, what have also needs higher expense and condition.Thereby in pastoral area, vast rural area, this disease is still tormenting many patients.
Summary of the invention: the present invention is directed to the problems referred to above, adopt Chinese herbal medicine to develop topical agent, its weight portion prescription is: Hydrargyrum chloratum Compositum 3-10 part, and Calomelas 5-15 part, Hydrargyri Oxydum Rubrum 3-10 part, Realgar 5-10 part is all got fine powder vaseline oil furnishing external application paste.This ointment method for making is simple, with low cost, and psoriasis is had specially good effect, and through nearly 3 years trying out, total effective rate can reach more than 95%.Dermatosiss such as eczema, verruca plana also there is certain curative effect.
Embodiment: Hydrargyrum chloratum Compositum, Calomelas, Hydrargyri Oxydum Rubrum, the Realgar of weight such as get, porphyrize mixes, with vaseline oil furnishing paste.
Usage: affected part coating skim, twice on the one.
Note not inlet eye, avoid and drink, avoid the pungent stimulating food of ichthyophagy.Warm calm place is suitable in medicine-feeding.If medicine-feeding place pain, in addition red and swollen, should reduce dose.Hydrargyrum allergy sufferers forbidding.
Pharmacodynamic analysis: Hydrargyrum chloratum Compositum belongs to the mixed crystallization of mercuric chloride and calomel, and severe toxicity and intensive corrosivity are arranged, and the effect of eliminating pus and toxicity is also arranged.Calomelas is the mercury compound that hydrargyrum, Alumen, Sal etc. are made with sublimed method, has the skin ulcer of holding back parasite killing, the effect of the relieving constipation of relieving oedema or abdominal distension through diuresis or purgation.Hydrargyri Oxydum Rubrum is the mercuride that hydrargyrum, Alumen, Borax are made into, and is close with the Calomelas drug effect, and the stronger osmosis of adhering to is arranged.Realgar is arsenical crystallization Ore, and often the form with red arsenic sulfide exists.Hydrargyrum chloratum Compositum toxicity is stronger, and is unsuitable oral.Though several toxicity in back are strong, relax, traditional Chinese medical science low dose commonly used is gone into ball and is loose for oral administration.Above-mentioned medicine is mixed, and strong toxicity is slow to differ, and the efficacy of a drug is lasting, and permeability is strong, than single use curative effect multiplication.
Modern medicine is a lot of to psoriatic cause of disease saying, mainly contains " heredity ", " virus ", " bacterial infection ", " Nervous and Mental Factors ", " endocrine factors ", " wound initiation ", " dysbolismus ", " immunocompromised " etc.This medicine is primarily aimed at the causes of disease such as biological virus and antibacterial.Because medicament is the arsenic mercurial, toxicity is stronger, and virus, antibacterial are had kill activity, skilfully use the corrosiveness of medicine in addition, obtain permeability preferably, take into account the violence and the persistency of drug effect, can't survival environment thereby made viral pathogenic bacteria, receive the effect for the treatment of the poisonous disease with poisonous drugs.
The clinical experiment situation:
1, diagnoses and treatment standard: the diagnosis and the treatment standard that adopt each opinion the 32 chapter of always touching upon in " modern dermatological " (publishing house of Shanghai Medical Univ publishes, Yang Guoliang, Wang Xiasheng chief editor) to be proposed.
2, experimental data: clinical treatment 44 examples, wherein cure 35 examples, account for 79.5%.Recur once in 2 years, through medication skin lesion disappearance person 3 people, 6.8%.Remission, but dissatisfied person 4 people of curative effect account for 9%.Ineffective person 2 people account for 4.5%, total effective rate 95.5%.
Claims (1)
1, the psoriasic medicine for external use of a kind of treatment is characterized in that: prescription by weight, and Hydrargyrum chloratum Compositum 3-10 part, Calomelas 5-15 part, Hydrargyri Oxydum Rubrum 3-10 part, Realgar 5-10 part is all got fine powder with vaseline oil furnishing external application paste.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011282800A CN1166367C (en) | 2001-10-11 | 2001-10-11 | Medicine for external application for curing psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011282800A CN1166367C (en) | 2001-10-11 | 2001-10-11 | Medicine for external application for curing psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1411817A CN1411817A (en) | 2003-04-23 |
| CN1166367C true CN1166367C (en) | 2004-09-15 |
Family
ID=4668154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011282800A Expired - Fee Related CN1166367C (en) | 2001-10-11 | 2001-10-11 | Medicine for external application for curing psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1166367C (en) |
-
2001
- 2001-10-11 CN CNB011282800A patent/CN1166367C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1411817A (en) | 2003-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Merz et al. | Fungating wounds–multidimensional challenge in palliative care | |
| EP2501366B1 (en) | Anti-viral composition | |
| CN101757117A (en) | Chinese herb medicine conditioner and preparation method thereof | |
| CN1100945A (en) | Broad spectrum detoxicating medicine for curing snakebite | |
| JP2000512270A (en) | Compositions and methods for the treatment of herpes simplex | |
| CN1166367C (en) | Medicine for external application for curing psoriasis | |
| CN1259098C (en) | Exterior-applied Chinese herbal medicine preparation for traumatic infection and inflammation-relieving acesodyne and its preparation method | |
| CN1067879C (en) | Preparation of medicament containing rare-earth for dermatomycosis | |
| CN107596355A (en) | A kind of Medical pain easing, the exterior-applied gel subsided a swelling, brought down a fever and preparation method thereof | |
| RU2284825C1 (en) | Method for treating abscesses, soft tissue phlegmons | |
| RU2419427C1 (en) | Method of prevention and complex treatment of urolithiasis after distant lithotripsy | |
| CN1102056C (en) | Plant night cream for treating pustular acne | |
| CN1093277A (en) | Bee glue ointment for curing chilblain | |
| CN1273161C (en) | Ru'an oral liquor | |
| CN112569297A (en) | External medicine for diabetic foot wound | |
| CN1079237C (en) | Dog bone scald medicine | |
| CN109394936A (en) | A kind of metal-inflicted wound that treating various wounds and inflammation dissipates and preparation method thereof | |
| RU2196590C1 (en) | Agent carbon-mercury hydrosulfate complex and method of treatment of infectious inflammatory sicknesses | |
| RU2107509C1 (en) | Method to treat and prevent bronchopulmonary diseases | |
| RU2172634C2 (en) | Bronchial asthma treatment method | |
| CN1189183C (en) | Yunnan Heiyao and its application in treating viral, bacterial and fungal diseases | |
| CN101129404A (en) | External use medicine for treating psoriasis | |
| CN101549002B (en) | Tincture for curing flat wart and method for preparing the same | |
| WO2006099789A1 (en) | A pharmaceutical preparation | |
| CN101912398B (en) | Medicine for treating urinary tract infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |